1. Ho KK, O’Sullivan AJ, Burt MG (2023) The physiology
of growth hormone (GH) in adults: translational journey to
GH replacement therapy. J Endocrinol 257: e220197
2. Le Roith D (1997) Seminars in medicine of the Beth Israel
Deaconess Medical Center. Insulin-like growth factors. N
Engl J Med 336: 633–640.
3. Brooks AJ, Waters MJ (2010) The growth hormone recep‐
tor: mechanism of activation and clinical implications. Nat
Rev Endocrinol 6: 515–525.
4. LeRoith D, Holly JMP, Forbes BE (2021) Insulin-like
growth factors: ligands, binding proteins, and receptors.
Mol Metab 52: 101245.
5. Casanueva FF (1992) Physiology of growth hormone
secretion and action. Endocrinol Metab Clin North Am 21:
483–517.
6. Melmed S (2019) Pathogenesis and diagnosis of growth
hormone deficiency in adults. N Engl J Med 380: 2551–
2562.
7. Bolier M, van der Lelij AJ, Janssens GO, van den HeuvelEibrink MM, Neggers SJCMM (2023) Long term safety
of growth hormone replacement therapy in survivors of
cancer and tumors of the pituitary region. Endocr Relat
Cancer 30: e230026.
8. Bartke A, Sun LY, Longo V (2013) Somatotropic signal‐
ing: trade-offs between growth, reproductive develop‐
ment, and longevity. Physiol Rev 93: 571–598.
9. Giustina A, Mazziotti G, Canalis E (2008) Growth hor‐
mone, insulin-like growth factors, and the skeleton.
Endocr Rev 29: 535–559.
10. Yakar S, Isaksson O (2016) Regulation of skeletal growth
and mineral acquisition by the GH/IGF-1 axis: lessons
from mouse models. Growth Horm IGF Res 28: 26–42.
11. Rhoads RP, Kim JW, Leury BJ, Baumgard LH, Segoale
N, et al. (2004) Insulin increases the abundance of the
growth hormone receptor in liver and adipose tissue of
periparturient dairy cows. J Nutr 134: 1020–1027.
12. Veldhuis JD, Roemmich JN, Richmond EJ, Bowers CY
(2006) Somatotropic and gonadotropic axes linkages in
infancy, childhood, and the puberty-adult transition.
Endocr Rev 27: 101–140.
13. Thissen JP, Ketelslegers JM, Underwood LE (1994)
Nutritional regulation of the insulin-like growth factors.
Endocr Rev 15: 80–101.
14. Merimee TJ, Zapf J, Froesch ER (1982) Insulin-like
growth factors in the fed and fasted states. J Clin Endocri‐
nol Metab 55: 999–1002.
15. Savage MO, Burren CP, Rosenfeld RG (2010) The con‐
tinuum of growth hormone-IGF-I axis defects causing
short stature: diagnostic and therapeutic challenges. Clin
Endocrinol (Oxf) 72: 721–728.
16. Baxter RC, Bryson JM, Turtle JR (1980) Somatogenic
receptors of rat liver: regulation by insulin. Endocrinology
107: 1176–1181.
17. Leung KC, Doyle N, Ballesteros M, Waters MJ, Ho KK
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
(2000) Insulin regulation of human hepatic growth hor‐
mone receptors: divergent effects on biosynthesis and sur‐
face translocation. J Clin Endocrinol Metab 85: 4712–
4720.
Inagaki T, Lin VY, Goetz R, Mohammadi M,
Mangelsdorf DJ, et al. (2008) Inhibition of growth hor‐
mone signaling by the fasting-induced hormone FGF21.
Cell Metab 8: 77–83.
Guarente L, Picard F (2005) Calorie restriction—the SIR2
connection. Cell 120: 473–482.
Gillum MP, Erion DM, Shulman GI (2011) Sirtuin-1 regu‐
lation of mammalian metabolism. Trends Mol Med 17: 8–
13.
Liu Y, Dentin R, Chen D, Hedrick S, Ravnskjaer K,
et al. (2008) A fasting inducible switch modulates gluco‐
neogenesis via activator/coactivator exchange. Nature
456: 269–273.
Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM,
et al. (2005) Nutrient control of glucose homeostasis
through a complex of PGC-1alpha and SIRT1. Nature
434: 113–118.
Frescas D, Valenti L, Accili D (2005) Nuclear trapping of
the forkhead transcription factor FoxO1 via Sirt-dependent
deacetylation promotes expression of glucogenetic genes.
J Biol Chem 280: 20589–20595.
Nie Y, Erion DM, Yuan Z, Dietrich M, Shulman GI, et al.
(2009) STAT3 inhibition of gluconeogenesis is downregu‐
lated by SirT1. Nat Cell Biol 11: 492–500.
Yamamoto M, Iguchi G, Fukuoka H, Suda K, Bando H, et
al. (2013) SIRT1 regulates adaptive response of the
growth hormone—insulin-like growth factor-I axis under
fasting conditions in liver. Proc Natl Acad Sci U S A 110:
14948–14953.
Yamamoto M, Takahashi Y (2018) The essential role of
SIRT1 in hypothalamic-pituitary axis. Front Endocrinol
(Lausanne) 9: 605.
Chung TT, Monson JP (2000) Hypopituitarism. In:
Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos
G, et al. (eds) Endotext. https://www.ncbi.nlm.nih.gov/
books/NBK278989/ accessed on November 27, 2022.
Husebye ES, Anderson MS, Kämpe O (2018) Autoim‐
mune polyendocrine syndromes. N Engl J Med 378:
2543–2544.
Guo CJ, Leung PSC, Zhang W, Ma X, Gershwin ME
(2018) The immunobiology and clinical features of
type 1 autoimmune polyglandular syndrome (APS-1).
Autoimmun Rev 17: 78–85.
Falorni A, Laureti S, Santeusanio F (2002) Autoantibodies
in autoimmune polyendocrine syndrome type II. Endocri‐
nol Metab Clin North Am 31: 369–389.
Takao T, Nanamiya W, Matsumoto R, Asaba K,
Okabayashi T, et al. (2001) Antipituitary antibodies in
patients with lymphocytic hypophysitis. Horm Res 55:
288–292.
874
Yamamoto et al.
32. O’Dwyer DT, Smith AI, Matthew ML, Andronicos NM,
Ranson M, et al. (2002) Identification of the 49-kDa auto‐
antigen associated with lymphocytic hypophysitis as
alpha-enolase. J Clin Endocrinol Metab 87: 752–757.
33. Cocco C, Brancia C, Corda G, Ferri GL (2017) The
hypothalamic-pituitary axis and autoantibody related dis‐
orders. Int J Mol Sci 18: 2322.
34. Iwama S, Welt CK, Romero CJ, Radovick S, Caturegli P
(2013) Isolated prolactin deficiency associated with serum
autoantibodies against prolactin-secreting cells. J Clin
Endocrinol Metab 98: 3920–3925.
35. De Bellis A, Bellastella G, Maiorino MI, Aitella E,
Lucci E, et al. (2016) Longitudinal behavior of autoim‐
mune GH deficiency: from childhood to transition age.
Eur J Endocrinol 174: 381–387.
36. De Bellis A, Colao A, Tirelli G, Ruocco G, Di Somma C,
et al. (2008) Autoimmunity as a possible cause of growth
hormone deficiency. J Endocrinol Invest 31: 1132–1134.
37. Sauter NP, Toni R, McLaughlin CD, Dyess EM,
Kritzman J, et al. (1990) Isolated adrenocorticotropin
deficiency associated with an autoantibody to a cortico‐
troph antigen that is not adrenocorticotropin or other
proopiomelanocortin-derived peptides. J Clin Endocrinol
Metab 70: 1391–1397.
38. De Bellis A, Pane E, Bellastella G, Sinisi AA, Colella C,
et al. (2011) Detection of antipituitary and antihypothala‐
mus antibodies to investigate the role of pituitary or
hypothalamic autoimmunity in patients with selective
idiopathic hypopituitarism. Clin Endocrinol (Oxf) 75:
361–366.
39. Scully KM, Rosenfeld MG (2002) Pituitary development:
regulatory codes in mammalian organogenesis. Science
295: 2231–2235.
40. Tatsumi K, Miyai K, Notomi T, Kaibe K, Amino N, et al.
(1992) Cretinism with combined hormone deficiency
caused by a mutation in the PIT1 gene. Nat Genet 1: 56–58.
41. Takeno R, Iguchi G, Kudo T, Takahashi K, Takahashi Y,
et al. (2003) A case of a possible acquired combined pitui‐
tary hormone deficiency. Folia Endocrinologica Japonica
79 (Suppl 3): 103 (In Japanese).
42. Takeno R, Takahashi Y, Iguchi G, Honda H, Nishizawa H,
et al. (2006) Acquired hypopituitarism characterized by
GH, PRL, and TSH deficiency Combined hypopituitarism:
detection of circulating PIT1 autoantibodies. Folia Endo‐
crinologica Japonica 82: 95 (In Japanese).
43. Saito T, Tojo K, Kuriyama G, Murakawa Y, Fujimoto K,
et al. (2004) A case of acquired deficiency of pituitary
GH, PRL and TSH, associated with type 1 diabetes melli‐
tus. Endocr J 51: 287–293.
44. Yamamoto M, Iguchi G, Takeno R, Okimura Y, Sano T,
et al. (2011) Adult combined GH, prolactin, and TSH
deficiency associated with circulating PIT-1 antibody in
humans. J Clin Invest 121: 113–119.
45. Harada Y, Mokubo A (2007) A case of acquired combined
hypopituitarism. Folia Endocrinologica Japonica 83: 774
(In Japanese).
46. Kotwal A, Stan M (2018) Thyrotropin receptor antibodiesan overview. Ophthal Plast Reconstr Surg 34(4S Suppl 1):
S20–S27.
47. Evoli A, Lancaster E (2014) Paraneoplastic disorders in
thymoma patients. J Thorac Oncol 9: S143–S147.
48. Hiyama TY, Matsuda S, Fujikawa A, Matsumoto M,
Watanabe E, et al. (2010) Autoimmunity to the sodiumlevel sensor in the brain causes essential hypernatremia.
Neuron 66: 508–522.
49. Bando H, Iguchi G, Fukuoka H, Yamamoto M, HidakaTakeno R, et al. (2014) Involvement of PIT-1-reactive
cytotoxic T lymphocytes in anti-PIT-1 antibody syndrome.
J Clin Endocrinol Metab 99: E1744–E1749.
50. Bando H, Iguchi G, Okimura Y, Odake Y, Yoshida K, et
al. (2017) A novel thymoma-associated autoimmune dis‐
ease: anti-PIT-1 antibody syndrome. Sci Rep 7: 43060.
51. Berrih-Aknin S, Le Panse R (2014) Myasthenia gravis: a
comprehensive review of immune dysregulation and etio‐
logical mechanisms. J Autoimmun 52: 90–100.
52. Wadhera A, Maverakis E, Mitsiades N, Lara PN, Fung
MA, et al. (2007) Thymoma-associated multiorgan auto‐
immunity: a graft-versus-host-like disease. J Am Acad
Dermatol 57: 683–689.
53. Anderson MS, Su MA (2016) AIRE expands: new roles in
immune tolerance and beyond. Nat Rev Immunol 16: 247–
258.
54. Cron MA, Maillard S, Villegas J, Truffault F, Sudres M, et
al. (2018) Thymus involvement in early-onset myasthenia
gravis. Ann N Y Acad Sci 1412: 137–145.
55. Wang Y, Thomas A, Lau C, Rajan A, Zhu Y, et al. (2014)
Mutations of epigenetic regulatory genes are common in
thymic carcinomas. Sci Rep 4: 7336.
56. Saito M, Fujiwara Y, Asao T, Honda T, Shimada Y, et al.
(2017) The genomic and epigenomic landscape in thymic
carcinoma. Carcinogenesis 38: 1084–1091.
57. Martinez-Ordoñez A, Seoane S, Cabezas P, Eiro N,
Sendon-Lago J, et al. (2018) Breast cancer metastasis to
liver and lung is facilitated by Pit-1-CXCL12-CXCR4
axis. Oncogene 37: 1430–1444.
58. Kanie K, Bando H, Iguchi G, Muguruma K, Matsumoto
R, et al. (2019) Pathogenesis of anti-PIT-1 antibody syn‐
drome: PIT-1 presentation by HLA class I on anterior
pituitary cells. J Endocr Soc 3: 1969–1978.
59. Yamamoto M, Iguchi G, Bando H, Kanie K, HidakaTakeno R, et al. (2020) Autoimmune pituitary disease:
new concepts with clinical implications. Endocr Rev 41:
261–272.
...
論文の公開元へ
